pocketful logo
Alpa Laboratories Ltd logo

Alpa Laboratories Ltd

NSE: ALPA BSE: 532878

₹61.70

(-1.25%)

Sat, 14 Mar 2026, 10:21 pm

mtf coin illustrationMTF 5x

Alpa Laboratories Share Price Live Chart

1 Day

0 (0%)

No Result Found

Summary

  • Market Cap

    129.19

  • Net Profit

    19.50

  • P/B

    1.28

  • Sector P/E

    32.86

  • P/E

    11.23

  • EV/EBITDA

    7.72

  • Debt/Equity (Industry)

    0.23

  • Interest Cover (Industry)

    10.03

  • ROCE (Industry)

    12.82

  • RONW (Industry)

    12.23

  • ROE

    12.06

  • ROCE

    15.76

  • Debt/Equity

    0.02

  • EPS (TTM)

    5.54

  • Dividend Yield

    0

  • Book Value

    87.12

  • Interest Cover

    112.57

Analysis

all

thumbs up icon

Pros

  • Alpa Laboratories is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Alpa Laboratories is profitable, therefore cash runway is not a concern.
  • Alpa Laboratories is profitable, therefore cash runway is not a concern.
  • Debt is covered by short term assets, assets are 310.1x debt.
  • Alpa Laboratories's cash and other short term assets cover its long term commitments.
thumbs up icon

Cons

  • Unable to evaluate Alpa Laboratories's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Alpa Laboratories's dividend against the top 25% market benchmark as the company has not reported any payouts.
  • Operating cash flow is negative therefore debt is not well covered.
  • Paresh's remuneration is higher than average for companies of similar size in India.
  • Alpa Laboratories is not covered by any analysts.

Read More

Financials

Read More

Ratios

Read More

Shareholding

ShareholdersDEC 2025SEPT 2025JUN 2025MAR 2025DEC 2024
Promoters57.2957.2957.2957.2957.29
FII0.360.350.360.400.35
DII00000
Public42.3542.3542.3442.3142.35
Government00000

Read More

Technical Analysis

RSI

33.61

MACD

-2.25

50 DMA

68.47

200 DMA

86.52

Support and Resistance

TypeR3R2R1PPS1S2S3
Classic92.4280.6473.3368.8661.5557.0845.30
Fibonacci80.6476.1473.3668.8664.3661.5857.08
Camarilla69.2568.1767.0968.8664.9363.8562.77

Pivots Level: Classic

R3

+23.56

92.42

R2

+11.78

80.64

R1

+4.46

73.33

68.86
68.86
Pivot Point
LTP: 60.87

S1

-7.32

61.55

S2

-11.78

57.08

S3

-23.56

45.30

Moving Average

SMAEMA

Period

Value

  • 10-EMA

    62.88

  • 20-EMA

    64.68

  • 30-EMA

    66.09

  • 50-EMA

    68.71

  • 100-EMA

    74.71

  • 200-EMA

    83.30

Read More

Corporate Actions

Announcement DatePurposeActionEx Date
11 Feb 2026board-meetingsQuarterly Results
14 Nov 2025board-meetingsQuarterly Results
12 Sept 2025agm
18 Sept 2024agm
20 Aug 2024agmAnnual General Meeting21 Sept 2024
05 Sept 2023agm
21 Aug 2023agmAnnual General Meeting22 Sept 2023
14 Sept 2022agm
20 Aug 2022agmAnnual General Meeting22 Sept 2022
07 Sept 2021agm

Read More

Peer Comparison

Alpa Laboratories Ltd logo

Alpa Laboratories Ltd

Sun Pharmaceutical Industries Ltd logo

Sun Pharmaceutical Industries Ltd

Dr Reddys Laboratories Ltd logo

Dr Reddys Laboratories Ltd

Torrent Pharmaceuticals Ltd logo

Torrent Pharmaceuticals Ltd

Divis Laboratories Ltd logo

Divis Laboratories Ltd

Cipla Ltd logo

Cipla Ltd

Read More

Alpa Laboratories Ltd About

Alpa Laboratories primary business lies in the manufacture and sale of Drugs and Chemicals.

Industry

Pharmaceuticals - Indian - Bulk Drugs & Formln

Founded

1988

Headquarters

CEO

Mahendra Singh Chawla

Employees

Contact

Website icon

Website

http://www.alpalabs.in

Email icon

Email

mail@alpalabs.in

Phone icon

Phone

91-731-4294567

Location icon

Location

33/2 Pigdamber, A B Road Rau, Indore, Madhya Pradesh, 453446

Read More

Alpa Laboratories Ltd Company History

YearHistory
2006
  • Started participation in international tenders for export.
  • Won a major tender from CMS, Sudan.
  • Launched Veterinary Division with a new face and ethical promotion of its Veterinary products in 5 states.
  • Launched Ethical division for its human products.
2007
  • Alpa Laboratories tied up with Vhermann Pharmaceutical Inc, Philippines for distribution of its products.
2010
  • The Company recommended a dividend of 10%.
2014
  • Ms. Monali Patel was appointed as the Company Secretary and Compliance Officer.
  • Alpa Laboratories sold its Unit-II to Ipca Laboratories Limited on a slump sale basis.
2015
  • Alpa Laboratories Ltd formed a wholly owned subsidiary named Norfolk Mercantile Private Ltd.

Read More

Deals

Client NameOrder SideQTYAvg PriceDate
AAKRAYA RESEARCH LLPSell246714140.2330 Sept 2024
NK SECURITIES RESEARCH PRIVATE LIMITEDBuy183809138.6930 Sept 2024
HRTI PRIVATE LIMITEDBuy155746139.4230 Sept 2024
QE SECURITIES LLPBuy203805139.7630 Sept 2024
NK SECURITIES RESEARCH PRIVATE LIMITEDSell183809138.7930 Sept 2024
QE SECURITIES LLPSell200761139.7530 Sept 2024
MUDUPULAVEMULA SURENDRANADHA REDDYBuy169278139.2130 Sept 2024
AAKRAYA RESEARCH LLPBuy246714140.0730 Sept 2024
MICROCURVES TRADING PRIVATE LIMITEDBuy122111139.5430 Sept 2024
PRADEEP KUMAR JAINSell125141138.8130 Sept 2024

Read More

Alpa Laboratories Ltd News

Alpa Labs Share Transfer via Gift Between Promoters

Alpa Laboratories reports inter se transfer of 21,940 shares (0.10%) from Bakulesh Chandulal Shah HUF to Vinit Shah as gift between immediate relatives on March 7, 2026.

09 Mar 2026

co actions results

Alpa Laboratories Company Secretary Resigns

Alpa Laboratories announces resignation of Company Secretary Ms. Srashiti Chopra effective March 25, 2026, citing personal reasons for departure from compliance role.

25 Feb 2026

stocks

Alpa Labs Q3FY26 Results: Revenue Up 13.5% YoY

Alpa Laboratories reported Q3FY26 revenue of Rs 2,967.12 lacs vs Rs 2,615.02 lacs YoY. Net profit declined to Rs 187.48 lacs from Rs 889.30 lacs in Q3FY25.

11 Feb 2026

co actions results

Alpa Laboratories Reports Strong Q1 Results with 1,177.59 Lakh Profit and Approves 37th AGM Notice

Alpa Laboratories Ltd. approved its unaudited standalone and consolidated financial results for the quarter ended June 30, 2025, and the notice for its 37th Annual General Meeting. The company reported standalone revenue from operations of 1,911.07 lakh compared to 2,144.37 lakh in the same quarter last year. Standalone profit for the quarter was 1,177.59 lakh, significantly higher than 512.45 lakh in June 2024. Other income increased substantially to 1,195.78 lakh from 516.02 lakh year-over-year, which included unrealized profit from fair market value increases in investments. On a consolidated basis, the company reported similar performance with profit of 1,176.78 lakh versus 509.63 lakh in the previous year quarter. The company operates in the single segment of Drugs & Chemicals. The results were reviewed by the Audit Committee and received an unmodified review conclusion from statutory auditors.

13 Aug 2025

earnings

Read More

Open Your Free Demat Account Now!

Step into a world of zero fees and limitless opportunities!

pocketful logo

2022-25 Pocketful. All rights reserved, Built with in India

Version -5.76

app image 1app image 2

Stocks:

AllABCDEFGHIJKLMNOPQRSTUVWXYZ

Explore

Calculatorsfooter arrow down icon
Popular Calculatorsfooter arrow down icon
Group Stocksfooter arrow down icon

Others:

NSEBSECDSLNSDLSEBIMCXMSEINCDEXNSE IFSCINDIA INXAccount Closure FormDP Investor CharterBroker Investor Charter

Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800